Holly M. Bauer

Partner

San Diego
holly.bauer@lw.com
+1.858.523.5482

PRACTICES

  • Emerging Companies & Growth
  • Environmental, Social & Governance (ESG)
  • Executive Compensation, Employment & Benefits
  • Mergers & Acquisitions
  • Public Company Representation
  • Tax

INDUSTRIES

  • Healthcare & Life Sciences
  • REITs
  • Technology
  • Video Gaming & esports

BAR QUALIFICATIONS

  • California

EDUCATION

  • JD, University of Virginia School of Law, 1995
  • BA, University of Southern California, 1991

PROFILE

Holly Bauer advises clients at all stages of corporate development on their most challenging compensation, employee benefits, and employment matters.

Holly combines creative problem-solving with impeccable judgment to guide clients on all aspects of:

  • Complex corporate transactions, including cross-border mergers and acquisitions, spin-offs, and initial public offerings
  • Public and emerging company representation on ongoing executive compensation and employee benefits matters, including employment arrangements, proxy materials, and securities filings related to executive compensation
  • Global equity or cash-based incentive plans, deferred compensation plans, and health and welfare plans

Drawing on her prior corporate law experience, Holly approaches each matter with a sophisticated understanding of the corporate and securities law aspects of executive compensation and benefits.

A recognized leader at the firm, Holly is Global Chair of the EEO Review Committee.

EXPERIENCE

Holly’s recent representative experience includes advising:

  • Fubo on its agreement with The Walt Disney Company to combine with Hulu + Live TV
  • Prometheus Biosciences in its US$10.8 billion sale to Merck
  • Aerovironment in its pending US$4.1 billion acquisition of Blue Halo
  • Extra Space Storage in its US$12.4 billion acquisition of Life Storage
  • NextGen Healthcare in its US$1.8 billion acquisition by Thoma Bravo
  • Zogenix in its US$2 billion sale to UCB
  • ChemoCentryx in its US$3.7 billion sale to Amgen
  • Icosavax in its US$1 billion sale to AstraZeneca, Zentalis
  • Ignyta in its US$1.7 billion acquisition by Roche
  • Ligand in its spin-off of OmniAb and the concurrent US$850 million merger of OmniAb with a special purpose acquisition company
  • Viasat in its:
    • US$2 billion sale of its Link 16 Tactical Data Links business to L3Harris Technologies
    • US$7.3 billion acquisition of Inmarsat
  • Sale of Truepill to PrivaPath Diagnostics (dba LetsGetChecked)
  • Golden State Foods in its sale of a controlling interest to Lindsay Goldberg
  • Avidity Biosciences, CG Oncology, Erasca, Boundless Bio, Icosavax, Mineralys, Playtika Holdings, Prometheus Biosciences and Tyra Biosciences in their Initial Public Offerings
  • Ongoing public company representation for: Avidity Biosciences, Beyond, Camping World, Erasca, Extra Space Storage, Inhibrx, Mineralys Therapeutics, Phathom Pharmaceuticals, SkyWest, Topgolf Callaway Brands, Tyra Biosciences,  Viasat, Zentalis Pharmaceuticals, and ZipRecruiter

Thought Leadership

  • “Reminder: Employers Must Report 2024 ISO and ESPP Transactions,” Latham & Watkins Client Alert, January 2025
  • “2025 Proxy Season: Strategically Preparing for the Upcoming Season,” Latham & Watkins Webcast, November 2024
  • “2024 Proxy Season: Lessons Learned and Coming Attractions,” Latham & Watkins Webcast, June 2024
  • “Paying the Premium: An Alternate Approach to Repricing Underwater Options,” Latham & Watkins publication, February 2024
  • “2024 Proxy Season: Considerations for Your Proxy Statement and Preparing for Your Annual Meeting,” Latham & Watkins Webcast, February 2024
  • “Key Compensation Items for 2024 Proxy Season and Beyond,” Latham & Watkins publication, February 2024
  • “Reminder: Employers Must Report 2023 ISO and ESPP Transactions,” Latham & Watkins Client Alert, January 2024
  • “2024 Proxy Season: Strategically Preparing for the Upcoming Season,” Latham & Watkins Webcast, November 2023
  • “SEC Clawback Rules: Practical Considerations and FAQs,” Latham & Watkins Client Alert, October 2023
  • “The Clawback Rules: Practical Considerations, Compliance, and Consequences,” Latham & Watkins Webcast, October 2023
  • “2023 Proxy Season: Lessons Learned and Coming Attractions,” Latham & Watkins Webcast, June 2023
  • “Nasdaq and NYSE File Proposed Listing Standards for Clawback Rules,” Latham & Watkins Client Alert, March 2023
  • “SEC Issues New ‘Pay Versus Performance’ Guidance,” Latham & Watkins Client Alert, February 2023